about
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAARTHIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort studyHIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trialHIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trialParallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate.The preventive phase I trial with the HIV-1 Tat-based vaccine.Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.
P50
Q28476094-5823ED8B-D5CD-4660-8B46-9ADFA6C83870Q30381447-0362BF67-0488-479F-8ACB-5EAAAD5595DEQ33864926-369F759F-0BCE-4BEC-A069-8B47C4FDD49AQ35552889-12CFC721-7DE9-4B3E-A1B4-6FB60F729D5CQ36986644-2CC5320F-588D-4A15-B8AD-57364CE55A8FQ37661107-81358FF6-93B8-41A3-A85D-1FDC54615F56Q38378021-8A1F7903-4E77-4A57-AFA4-116024C7819BQ51828622-9C63A074-53EF-4041-BF08-FA315F838E82
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Giovanni Paniccia
@ast
Giovanni Paniccia
@en
Giovanni Paniccia
@es
Giovanni Paniccia
@nl
Giovanni Paniccia
@sl
type
label
Giovanni Paniccia
@ast
Giovanni Paniccia
@en
Giovanni Paniccia
@es
Giovanni Paniccia
@nl
Giovanni Paniccia
@sl
prefLabel
Giovanni Paniccia
@ast
Giovanni Paniccia
@en
Giovanni Paniccia
@es
Giovanni Paniccia
@nl
Giovanni Paniccia
@sl
P106
P1153
26030003100
P21
P31
P496
0000-0002-9850-5802